These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19473407)

  • 1. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A.
    Young JH; Liu HC; Hsueh EJ; Huang ML; Peng CT; Chen RL; Maas-Enriquez M; Achilles K
    Haemophilia; 2009 Jul; 15(4):968-70. PubMed ID: 19473407
    [No Abstract]   [Full Text] [Related]  

  • 2. Maintenance of treatment logs by haemophilia patients.
    du Treil S; Rice J; Leissinger CA
    Haemophilia; 2010 May; 16(3):545-7. PubMed ID: 20050930
    [No Abstract]   [Full Text] [Related]  

  • 3. Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII.
    Bajwa N; Enriquez MM; Gorina E; Lemm G
    Haemophilia; 2009 Mar; 15(2):597-600. PubMed ID: 19187195
    [No Abstract]   [Full Text] [Related]  

  • 4. Fifteen years of population based experience in Finland with a plasma-derived monoclonal purified factor VIII concentrate.
    Mäkipernaa A; von Bonsdorff L
    Haemophilia; 2008 May; 14(3):612-4. PubMed ID: 18312362
    [No Abstract]   [Full Text] [Related]  

  • 5. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A.
    Delumeau JC; Ikegawa C; Yokoyama C; Haupt V
    Thromb Haemost; 2008 Jul; 100(1):32-7. PubMed ID: 18612535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
    Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim data on long-term efficacy, safety and tolerability of a plasma-derived factor VIII concentrate in 109 patients with severe haemophilia A.
    Nemes L; Pollmann H; Becker T
    Haemophilia; 2012 Jul; 18(4):496-502. PubMed ID: 22250808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
    Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
    Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
    Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
    Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.
    Meijer K; Rauchensteiner S; Santagostino E; Platokouki H; Schutgens RE; Brunn M; Tueckmantel C; Valeri F; Schinco PC
    Haemophilia; 2015 Jan; 21(1):e19-25. PubMed ID: 25458982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A.
    Steele MR; Nagel K; Chan AK
    Haemophilia; 2014 Jan; 20(1):e100-1. PubMed ID: 24251412
    [No Abstract]   [Full Text] [Related]  

  • 13. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
    Singleton E; Smith J; Kavanagh M; Nolan B; White B
    Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
    Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment for hemophilia.
    FDA Consum; 2003; 37(6):5. PubMed ID: 14983810
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
    Saxena K; Lalezari S; Oldenburg J; Tseneklidou-Stoeter D; Beckmann H; Yoon M; Maas Enriquez M
    Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Personification of the standard treatment of patients with hemophilia A (results of a multicenter Russian open-labeled prospective study evaluating the use of haemoctin)].
    Zozulia NI; Pliushch OP
    Ter Arkh; 2010; 82(4):56-61. PubMed ID: 20481218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressing towards optimal management of haemophilia A patients with inhibitors. Foreword.
    Tarantino MD
    Haemophilia; 2013 Jan; 19 Suppl 1():1. PubMed ID: 23278992
    [No Abstract]   [Full Text] [Related]  

  • 19. FVIII dosages in persons with haemophilia A treated with extended half-life products: From local biology to optimized patient management.
    Perrier-Cornet A; Philippe A; Lambert T; d'Oiron R; Rafowicz A; Lavenu-Bombled C; Combe S; Gillibert A; Proulle V
    Haemophilia; 2019 Nov; 25(6):e361-e363. PubMed ID: 31206947
    [No Abstract]   [Full Text] [Related]  

  • 20. [Inhibitor development after changing FVIII/IX products in patients with haemophilia].
    Kocher S; Asmelash G; Makki V; Müller S; Krekeler S; Alesci S; Miesbach W
    Hamostaseologie; 2012; 32 Suppl 1():S39-42. PubMed ID: 22961330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.